# Developmental Research Program 1

> **NIH NIH P50** · BAYLOR COLLEGE OF MEDICINE · 2022 · $124,686

## Abstract

PROJECT SUMMARY
The goal of the Lymphoma SPORE Developmental Research Program (DRP) is to support innovative
translational research projects that may in the future develop into full projects. To achieve this objective, the
DRP will solicit submission of novel projects with translational potential in lymphoma and chronic lymphocytic
leukemia (CLL). The program will be led by directors Drs. Malcolm Brenner and Margaret Goodell, who
continue as DRP leaders, and new co-leader Dr George Carrum who brings with him clinical expertise and a
commitment to increasing diversity among DRP awardees. Candidate projects will be reviewed by a panel
with expertise in translational research and the most promising proposals will be selected for support. Our
goal for each supported project is that it will either develop into a full SPORE project or secure peer-reviewed
funding as an independent project. We will continue to achieve this goal by fully incorporating the leaders of
developmental projects into the SPORE, enabling them to take advantage of the expertise of SPORE
investigators in translating their project from the bench to bedside.
 In the last four years, our Lymphoma SPORE DRP has supported a broad portfolio of 9 projects by
diverse investigators from five different Departments and Centers within Baylor College of Medicine as well
as other institutions in the Texas Medical Center (one award to Texas A&M and one to Rice University) and
nationally (one award to Moffitt Cancer Center). Five female and two underrepresented minority investigators
have led the nine DRP projects supported in most recent funding period and have already been leveraged to
obtain $8.65 million in peer-reviewed funding from an initial investment of $450,000. Long-term follow up of
the 28 projects funded in the first two cycles of our SPORE shows 46 publications that have been cited over
4,300 times and over $18.4 million dollars in peer-reviewed funding from an investment of $1.4 million through
our DRP. In collaboration with the Administrative Core, the DRP directors will continue to use this program to
test and develop novel strategies for the treatment of lymphoma and CLL, and will also collect data to evaluate
the success of the DRP program, including seeking the feedback and advice of our internal and external
advisory boards.

## Key facts

- **NIH application ID:** 10495083
- **Project number:** 2P50CA126752-16
- **Recipient organization:** BAYLOR COLLEGE OF MEDICINE
- **Principal Investigator:** MALCOLM K. BRENNER
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $124,686
- **Award type:** 2
- **Project period:** 2007-09-11 → 2027-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10495083

## Citation

> US National Institutes of Health, RePORTER application 10495083, Developmental Research Program 1 (2P50CA126752-16). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10495083. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*